Anderson D: Cystic fibrosis of pancreas and its relation to celiac disease. Am J Dis Child 1938, 56:344–349.
Feranchak AP, Sokol RJ: Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis 2001, 21:471–488.
Colombo C, Battezzati PM, Podda M: Hepatobiliary disease in cystic fibrosis. Semin Liver Dis 1994, 14:259–269.
Oppeinheimer E, Esterly J: Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975, 86:683–689.
Vawter GF, Shwachman H: Cystic fibrosis in adults: an autopsy study. Pathol Annu 1979, 14:357–382.
Scott-Jupp R, Lama M, Tanner MS: Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991, 66:698–701.
Colombo C, Battezzati PM, Crosignani A, et al.: Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36:1374–1382. This paper highlights the need for prospective evaluation of patients with predetermined measurable variables and thus accurately determines the incidence of liver disease in CF patients
Lindblad A, Glaumann H, Strandvik B: Natural history of liver disease in cystic fibrosis. Hepatology 1999, 30:1151–1158. This paper also reports on a prospective analysis of CF patients using predetermined variables including histology.
Efrati O, Barak A, Modan-Moses D, et al.: Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003, 15:1073–1078.
Debray D, Lykavieris P, Gauthier F, et al.: Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol 1999, 31:77–83.
Rovsing H, Sloth K: Micro-gallbladder and biliary calculi in mucoviscidosis. Acta Radiol Diagn (Stockh) 1973, 14:588–592.
Nagel RA, Westaby D, Javaid A, et al.: Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989, 2:1422–1425.
Gaskin KJ, Waters DL, Howman-Giles R, et al.: Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med, 1988, 318:340–346.
Kerem E, Corey M, Kerem BS, et al.: The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (delta F508). N Engl J Med 1990, 323:1517–1522.
Knight RA: Genetics of cystic fibrosis. Br J Hosp Med 1992, 47:502–506.
Santis G, Osborne L, Knight RA, Hodson ME: Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet 1990, 336:1081–1084.
Davis PB, Drumm M, Konstan MW: Cystic fibrosis. Am J Respir Crit Care Med 1996, 154:1229–1256.
De Arce M, O’Brien S, Hegarty J, et al.: Deletion delta F508 and clinical expression of cystic fibrosis-related liver disease. Clin Genet 1992, 42:271–272.
Duthie A, Doherty DG, Williams C, et al.: Genotype analysis for delta F508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology 1992, 15:660–664.
Cohn JA, Strong TV, Picciotto MR, et al.: Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993, 105:1857–1864. The first description of the localization of the CFTR to the biliary epithelium.
Lindblad A, Hultcrantz R, Strandvik B: Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 1992, 16:372–381.
Duthie A, Doherty DG, Donaldson PT, et al.: The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol 1995, 23:532–537.
Mieli-Vergani G, Psacharopoulos HT, Nicholson AM, et al.: Immune responses to liver membrane antigens in patients with cystic fibrosis and liver disease. Arch Dis Child 1980, 55:696–701.
Besancon F, Przewlocki G, Baro I, et al.: Interferon-gamma downregulates CFTR gene expression in epithelial cells. Am J Physiol 1994, 267:C1398-C1404.
Donaldson PT, Farrant JM, Wilkinson ML, et al.: Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991, 13:129–133.
Sheth S, Shea JC, Bishop MD, et al.: Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003, 113:286–292.
Flamant C, Henrion-Caude A, Boelle PY, et al.: Glutathione-Stransferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenetics 2004, 14:295–301. This paper provides a possible explanation for the variability in the presentation and severity of CF-related liver disease and examines the possibility that polymorphisms in the GSTP1 genes expressed in human hepatic stellate and biliary epithelial cells may account for this variability.
Henrion-Caude A, Flamant C, Roussey M, et al.: Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 2002, 36:913–917.
Dray-Charier N, Paul A, Scoazec JY, et al.: Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients. Hepatology 1999, 29:1624–1634.
van Haren EH, Hopman WP, Jansen JB, et al.: Increased plasma cholecystokinin levels and small gall bladders in adult patients with cystic fibrosis. Clin Sci (Lond) 1991, 81:85–89.
Angelico M, Gandin C, Canuzzi P, et al.: Gallstones in cystic fibrosis: a critical reappraisal. Hepatology 1991, 14:768–775.
Smith FE, Doughty IM, David TJ, et al.: Severe jaundice in two infants with cystic fibrosis. J R Soc Med 1996, 89:289P-290P.
Valman HB, France NE, Wallis PG: Prolonged neonatal jaundice in cystic fibrosis. Arch Dis Child 1971, 46:805–809.
Torstenson OL, Humphrey GB, Edson JR, Warwick WJ: Cystic fibrosis presenting with severe hemorrhage due to vitamin K malabsorption: a report of three cases. Pediatrics 1970, 45:857–861.
Stern RC, Rothstein FC, Doershuk CF, Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1986, 5:35–40.
Patrick MK, Howman-Giles R, De Silva M, et al.: Common bile duct obstruction causing right upper abdominal pain in cystic fibrosis. J Pediatr 1986, 108:101–102.
Magruder MJ, Munden MM: Intrahepatic microlithiasis: another gastrointestinal complication of cystic fibrosis. J Ultrasound Med 1997, 16:763–765.
Tanner MS, Taylor CJ: Liver disease in cystic fibrosis. Arch Dis Child 1995, 72:281–284.
Ling SC, Wilkinson JD, Hollman AS, et al.: The evolution of liver disease in cystic fibrosis. Arch Dis Child 1999, 81:129–132.
Gerling B, Becker M, Staab D, Schuppan D: Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N Engl J Med 1997, 336:1611–1612.
Wyatt HA, Dhawan A, Cheeseman P, et al.: Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. Arch Dis Child 2002, 86:190–193.
Williams SG, Evanson JE, Barrett N, et al.: An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995, 22:513–521.
Williams SM, Goodman R, Thomson A, et al.: Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol 2002, 57:365–370.
Picciotto A, Ciravegna G, Lapertosa G, Celle G: Percutaneous or laparoscopic needle biopsy in the evaluation of chronic liver disease?
Am J Gastroenterol 1984, 79:567–568.
O’Brien S, Keogan M, Casey M, et al.: Biliary complications of cystic fibrosis. Gut 1992, 33:387–391.
Durieu I, Pellet O, Simonot L, et al.: Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999, 30:1052–1056.
Chase HP, Long MA, Lavin MH: Cystic fibrosis and malnutrition. J Pediatr 1979, 95:337–347.
Heymans HS: Gastrointestinal dysfunction and its effects on nutrition in CF. Acta Paediatr Scand Suppl 1989, 363:74–78; discussion 78-79.
Leuschner U, Fischer H, Kurtz W, et al.: Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled doubleblind trial. Gastroenterology 1989, 97:1268–1274.
Beuers U, Boyer JL, Paumgartner G: Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998, 28:1449–1453.
Colombo C, Battezzati PM, Podda M, et al.: Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a doubleblind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996, 23:1484–1490.
O’Brien SM, Campbell GR, Burke AF, et al.: Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatol 1996, 8:477–483.
Colombo C, Crosignani A, Assaisso M, et al.: Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a doseresponse study. Hepatology 1992, 16:924–930.
Lindblad A, Glaumann H, Strandvik B: A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27:166–174.
Snyder CL, Ferrell KL, Saltzman DA, et al.: Operative therapy of gallbladder disease in patients with cystic fibrosis. Am J Surg 1989, 157:557–561.
McGrath DS, Short C, Bredin CP, et al.: Laparoscopic cholecystectomy in adult cystic fibrosis. Ir J Med Sci 1997, 166:70–71.
Edelman DS: Laparoscopic cholecystectomy under continuous epidural anesthesia in patients with cystic fibrosis. Am J Dis Child 1991, 145:723–724.
Fridell JA, Bond GJ, Mazariegos GV, et al.: Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center’s experience. J Pediatr Surg 2003, 38:1152–1156.
Molmenti EP, Squires RH, Nagata D, et al.: Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003, 7:93–97.
Noble-Jamieson G, Barnes N, Jamieson N, et al.: Liver transplantation for hepatic cirrhosis in cystic fibrosis. J R Soc Med 1996, 89(Suppl 27):31–37.
Couetil JP, Houssin DP, Soubrane O, et al.: Combined lung and liver transplantation in patients with cystic fibrosis: a 4 1/2 year experience. J Thorac Carciovasc Curg 1995, 110:1415–1422.
Grubman SA, Fang SL, Mulberg AE, et al.: Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 1995, 108:584–592.
Yang Y, Raper SE, Cohn JA, et al.: An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci U S A 1993, 90:4601–4605.
Zabner J, Couture LA, Gregory RJ, et al.: Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993, 75:207–216.
Grubb BR, Pickles RJ, Ye H, et al.: Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994, 371:802–806.
Egan ME, Pearson M, Weiner SA, et al.: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304:600–602. A cautious optimism: This paper reports the possibility of activating the F508 mutant forms of the CFTR gene as a potential strategy for treating CF with turmeric.